Matinas BioPharma Holdings (MTNB) Other Accumulated Expenses (2018 - 2025)

Matinas BioPharma Holdings (MTNB) has 7 years of Other Accumulated Expenses data on file, last reported at $120000.0 in Q3 2025.

• Other Accumulated Expenses for Q3 2025 came in at $120000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $120000.0 (changed N/A YoY), and the FY2024 annual result was $1.5 million, changed N/A from the prior year.
• Other Accumulated Expenses retreated to $120000.0 in Q3 2025 per MTNB's latest filing, from $482000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.5 million in Q4 2024 and troughed at $88000.0 in Q4 2022.
• A 4-year average of $634833.3 and a median of $592000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses soared 9299900.0% in 2021, then tumbled 90.21% in 2022.
• A 4-year view of Other Accumulated Expenses shows it stood at $899000.0 in 2021, then plunged by 90.21% to $88000.0 in 2022, then jumped by 1614.77% to $1.5 million in 2024, then plunged by 92.05% to $120000.0 in 2025.
• Business Quant data shows MTNB's Other Accumulated Expenses at $120000.0 in Q3 2025, $482000.0 in Q2 2025, and $922000.0 in Q1 2025.